pSivida Corp (PSDV) Reports ILUVIEN® To Be Funded By UK’s National Health Service For Treatment Of Pseudophakic Chronic DME Patients Following Issuance Of Final National Institute for Clinical Excellence (NICE) Guidance
12/2/2013 9:11:34 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that on November 27, 2013, the United Kingdom’s National Institute for Health and Care Excellence (NICE) published final guidance recommending ILUVIEN® as a treatment option for pseudophakic patients (those who have had cataract surgery) with chronic Diabetic Macular Edema (DME) insufficiently responsive to available therapies, subject to a patient access scheme. NICE requires clinical commissioning groups, the National Health Service England and local public health authorities to comply with the recommendation in the final guidance within three months of its date of publication.
Help employers find you! Check out all the jobs and post your resume.
comments powered by